Article
Oncology
Maximilian Gassenmaier, Max M. Lenders, Andrea Forschner, Ulrike Leiter, Benjamin Weide, Claus Garbe, Thomas K. Eigentler, Nikolaus B. Wagner
Summary: LDH and S100B are suitable serum biomarkers for detecting response and disease progression during therapy with BRAFi in patients with metastatic melanoma. S100B has stronger correlation with treatment response and is more accurate in predicting progressive disease. Close monitoring of S100B levels is recommended for early detection of disease progression during BRAFi treatment.
Article
Immunology
Elias A. T. Koch, Niels Schaft, Mirko Kummer, Carola Berking, Gerold Schuler, Kenichiro Hasumi, Jan Doerrie, Beatrice Schuler-Thurner
Summary: Uveal melanoma is a rare disease with poor response to traditional therapies. Researchers designed a trial using personalized dendritic cell vaccines to activate the immune system and potentially improve clinical outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Eszter Anna Janka, Tuende Varvoelgyi, Zoltan Sipos, Alexandra Soos, Peter Hegyi, Szabolcs Kiss, Fanni Dembrovszky, Dezso Csupor, Patrik Keringer, Daniel Pecsi, Margit Solymar, Gabriella Emri
Summary: In a systematic review and meta-analysis involving 1,033 patients with resected melanoma, serum S100B showed significantly better discriminative ability for disease relapse compared to serum LDH. However, in a risk of death analysis with 1,987 patients included, the prognostic performance of serum S100B was independent but not superior to serum LDH.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Anastasia Prokopi, Christoph H. Tripp, Bart Tummers, Florian Hornsteiner, Sarah Spoeck, Jeremy Chase Crawford, Derek R. Clements, Mirjana Efremova, Katharina Hutter, Lydia Bellmann, Giuseppe Cappellano, Bruno L. Cadilha, Sebastian Kobold, Louis Boon, Daniela Ortner, Zlatko Trajanoski, Suzie Chen, Tanja D. de Gruijl, Juliana Idoyaga, Douglas R. Green, Patrizia Stoitzner
Summary: Immunotherapy with checkpoint inhibitors has shown impressive results in patients with melanoma, but many still do not benefit from this treatment due to factors such as lack of tumor-infiltrating T cells and loss of intratumoral dendritic cells. In a melanoma mouse model, researchers found that tumor progression is characterized by upregulation of checkpoint molecules and gradual loss of dermal conventional DC 2 subset. Monotherapy with checkpoint blockade was not effective, but boosting DC numbers and activation increased tumor immunogenicity, leading to improved T cell function and delayed tumor growth when combined with antibodies against PD-1 and TIM-3. The study highlights the importance of skin DC in cancer immunotherapy and suggests that restoring DC function is key to enhancing tumor immunogenicity and responsiveness to checkpoint blockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Jingjing Wang, Yu Liu, Weihua Ni, Xinjie Wu, Jianhong Zhou, Zenan Zhang, Hongyue Zhou, Nannan Zhang, Mengyu Jiang, Qianyu Sang, Hongyan Yuan, Guixiang Tai
Summary: This study found that TRAF6 overexpression promotes the maturation of dendritic cells (DCs) and activates Th1 responses. In a therapeutic tumor model, TRAF6-overexpressing DCs significantly inhibited tumor growth and enhanced specific immune responses.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Xueying Tang, Jiashuo Zhang, Dezhi Sui, Qiongfen Yang, Tianyu Wang, Zihan Xu, Xiaoya Li, Xin Gao, Xinyang Yan, Xinrong Liu, Yanzhi Song, Yihui Deng
Summary: This study developed a SA-modified mRNA vaccine that achieved successful DC targeting and efficient endosomal/lysosomal escape, resulting in higher transfection efficiency and lower side effects in DCs.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Oncology
Yoke Seng Lee, Liam J. O'Brien, Carina M. Walpole, Frances E. Pearson, Ingrid M. Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J. Radford
Summary: The study found that the number of CD141(+) dendritic cells in the blood of melanoma patients was significantly reduced, and these cells exhibited impaired function after peripheral stimulation. In non-responding patients, the number and function of these cells continued to decline during treatment. Indirectly expanding and activating CD141(+) dendritic cells in vivo with Flt3L and a TLR3 agonist can enhance the efficacy of anti-PD-1 treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Medical Laboratory Technology
Elisa A. Rozeman, Judith M. Versluis, Ruben Moritz, Sofie Wilgenhof, Johannes V. van Thienen, John B. A. G. Haanen, Michel M. van de Heuvel, Christian U. Blank, Huub H. van Rossum
Summary: This study evaluated if early increases in S100B or lactate dehydrogenase (LDH) could predict non-responsiveness to anti-PD-1 therapy in advanced melanoma patients. The findings revealed that early increases in S100B or LDH serve as strong parameters for non-responsiveness to anti-PD-1 in advanced melanoma patients.
CLINICA CHIMICA ACTA
(2022)
Review
Immunology
Zhihua Xiao, Ruiqi Wang, Xuyan Wang, Haikui Yang, Jiamei Dong, Xin He, Yang Yang, Jiahao Guo, Jiawen Cui, Zhiling Zhou
Summary: Dendritic cells (DCs) are professional antigen-presenting cells that play a crucial role in initiating and maintaining anti-tumor immunity. However, the immunosuppressive tumor microenvironment (TME) can lead to DC dysfunction and impaired anti-tumor immune response. Current research focuses on restoring or enhancing the activity of DCs through immunotherapeutic strategies, including DC-based vaccines, to better control tumors.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, Research & Experimental
Dong Wang, Qian Cui, Yan Jie Yang, A. Qing Liu, Guan Zhang, Jian Chun Yu
Summary: Dendritic cells play a crucial role in tumor immunotherapy, and Astragalus polysaccharide can enhance their antitumor effects. Understanding the role of DC subgroups in the TME helps evaluate the efficacy of tumor immunotherapy.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Immunology
Hinda Najem, Anantha Marisetty, Craig Horbinski, James Long, Jason T. Huse, Isabella C. Glitza Oliva, Sherise D. Ferguson, Priya U. Kumthekar, Derek A. Wainwright, Peiwen Chen, Maciej S. Lesniak, Jared K. Burks, Amy B. Heimberger
Summary: The TME of LMD lacks CD3+ T cells but is enriched in immune suppression and innate immunity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Eszter Anna Janka, Beatrix Vanyai, Imre Lorinc Szabo, Tuende Toka-Farkas, Tunde Varvolgyi, Aniko Kapitany, Andrea Szegedi, Gabriella Emri
Summary: This study aimed to determine the prognostic performance of demographics, clinical and histological prognostic markers, and baseline serum S100B and LDH levels in advanced melanoma patients treated with anti-PD-1. The results showed that M1c and M1d stage, pT4b category, elevated baseline serum S100B and LDH levels were associated with poor survival. Combining clinical, histological, and serum prognostic markers could contribute to a prognostic model.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell Biology
Samrat Roy Choudhury, Billie Heflin, Erin Taylor, Brian Koss, Nathan L. Avaritt, Alan J. Tackett
Summary: Overexpression of S100B is commonly used for disease-staging and prognostic outcomes in melanoma patients. Although there is weak correlation between S100B overexpression and alterations in its copy number or DNA methylation in primary patient samples, the transcriptional start site and upstream promoter of the gene are epigenetically primed in melanoma cells with predicted enrichment of activating transcription factors.
Review
Oncology
Yasuyuki Saito, Satomi Komori, Takenori Kotani, Yoji Murata, Takashi Matozaki
Summary: This review outlines the role of type-2 conventional dendritic cells (cDC2s) in antitumor immunity and summarizes the latest progress in cancer vaccination and cDC2-targeted cancer immunotherapy.
Article
Chemistry, Multidisciplinary
Vajiheh Jahani, Mona Yazdani, Ali Badiee, Mahmoud Reza Jaafari, Leila Arabi
Summary: The immunosuppressive tumor microenvironment limits the efficacy of cancer vaccines. Combining liposomal celecoxib with DC vaccines can normalize the tumor microenvironment and enhance the antitumor response.
JOURNAL OF CONTROLLED RELEASE
(2023)